Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.67 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.67 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | RARB | P10826 | 4/20 | 0.42 |
| ▸ | THRA | P10827 | 4/20 | 0.42 |
| ▸ | THRB | P10828 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RARA | P10276 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8568072 | 1.00 | CYP4A11 (0.67) | CYP4A11CYP4F2PPARACA2CA12 | |
| SCHEMBL1560634 | 0.98 | CYP4A11 (0.69) | CYP4A11CYP4F2PPARACA2CA12 | |
| SCHEMBL7855043 | 0.94 | CYP4A11 (0.68) | CYP4A11CYP4F2PPARACA2CA12 | |
| SCHEMBL2207588 | 0.87 | CYP4A11 (0.60) | CYP4A11CYP4F2PPARACA2CA12 | |
| SCHEMBL8293510 | 0.86 | RARB (0.55) | CYP4A11CYP4F2RARBTHRATHRB | |
| SCHEMBL2659321 | 0.86 | CYP4A11 (0.51) | CYP4A11CYP4F2CA2CA12CA1 | |
| SCHEMBL1743772 | 0.85 | MAPT (0.54) | CYP4A11CYP4F2NR1H2MAPTFAAH | |
| SCHEMBL22964323 | 0.85 | CYP4A11 (0.51) | CYP4A11CYP4F2CA2CA12CA1 | |
| SCHEMBL6209198 | 0.84 | CYP4A11 (0.50) | CYP4A11CYP4F2CA2CA12CA1 | |
| SCHEMBL21577923 | 0.83 | HSD17B10 (0.55) | CYP4A11CYP4F2NR1H2MAPTFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11236051-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210009528-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2021-01-14 | — | — | US | disclosed |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | CYP4A11 553/4885CYP4F2 2100/4885PPARA 2790/4885 |
| US-20210009528-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | CYP4A11 553/4885CYP4F2 2100/4885PPARA 2790/4885 |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | CYP4A11 595/4885CYP4F2 2153/4885PPARA 2833/4885 |
| US-11236051-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | CYP4A11 553/4885CYP4F2 2100/4885PPARA 2790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.